Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

CVS Health is turning up the heat on Eli Lilly and Novo Nordisk, releasing a white paper arguing that GLP-1 drugs need to cost $350 a month or less for employers to actually save money. Right now, plan sponsors spend $13,300 more on prescriptions per person than they save on medical costs. With employer coverage of GLP-1s already shrinking, CVS says a price cut is the only way to keep these effective drugs accessible.
CVS Health is making a bold move to pressure GLP-1 drugmakers, releasing a white paper that argues the popular weight loss and diabetes drugs need to be priced at $350 per month or less for employers to break even — let alone save money. Currently, employers pay between $617 and $766 a month for GLP-1s, and the math just doesn't add up for plan sponsors footing the bill.
The analysis, based on three years of Aetna claims data, shows GLP-1s do deliver real clinical benefits — but the prescription costs still outpace the savings. As a result, employer coverage of GLP-1s is quietly eroding, with nearly 28% of employers planning to drop or reduce weight management coverage next year.
By the Numbers:
Why it matters: With the global GLP-1 market projected to hit $190 billion by 2035, pricing will determine whether millions of eligible patients can actually access these drugs. CVS's public pressure campaign could be a turning point in the broader affordability debate.